摘要
目的 :观察早期应用阿托伐汀对急性冠状动脉综合征患者的可溶性细胞间黏附分子 1(solubleintercellularadhesionmolecules 1,sICAM 1)和可溶性血管细胞黏附分子 1(solublevascularcellad hesionmolecules 1,sVCAM 1)的影响 ,探讨阿托伐汀降低急性冠状动脉综合征炎症反应的可能机制。方法 :稳定型心绞痛 30例 ,急性冠状动脉综合征 6 8例 ,后者再分为两亚组 :阿托伐汀组 35例 ,非阿托伐汀组 33例。用酶联免疫吸附法测定急性冠状动脉综合征患者入院后第 1、 3、 5、 7、 14日的sICAM 1和sVCAM 1水平 ,观察阿托伐汀对其sICAM 1和sVCAM 1水平的影响。结果 :急性冠状动脉综合征患者入院时血清sICAM 1和sVCAM 1水平均比稳定型心绞痛组明显增高 (P <0 0 1)。治疗后急性冠状动脉综合征两亚组的血清sICAM 1和sVCAM 1水平均有不同程度的降低 ,其中阿托伐汀组的下降更显著。结论 :阿托伐汀可以降低炎症反应 ,在急性冠状动脉综合征的早期治疗中起重要作用。
Objective: To observe the influence of atorvastatin on so lu ble intercellular adhesion molecules-1(sICAM-1)and soluble vascular cell adhes ion molecules-1 (sVCAM-1) in patients with acute coronary syndrome(ACS),to pro be the mechanism of atorvastatin in lowering inflammatory reaction in patients w ith acute coronary syndrome. Methods: Patients were divided into tw o groups:30 patients with stable angina pectoris(SAP),68 patients with ACS. The latter group were divided into two sub-groups randomly: atorvastatin group and non-atorvastatin group. Serum concentrations of sICAM-1 and sVCAM-1 in pati ents with ACS were mea-sured by enzyme-linked immunosorbentassay(ELISA) on da y 1,3,5,7 and 14 after hospitalization. Results: Serum concentratio ns of sICAM-1 and sVCAM-1 in patients with ACS were higher than of SAP group ( P<0.01).In two sub-groups of ACS group, serum concentrations of sICAM-1 and sVCAM-1 in atorvastatin group decreased more significantly than th e other. Conclusion: Atorvastatin may decrease inflammatory reactio n and play a pivotal role in early therapy of ACS patients. [
出处
《新医学》
北大核心
2004年第12期722-724,共3页
Journal of New Medicine
